|
1
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar
|
|
2
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barzaman K, Karami J, Zarei Z,
Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and
Farahmand L: Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol. 84:1065352020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Veronesi U, Boyle P, Goldhirsch A,
Orecchia R and Viale G: Breas cancer. Lancet. 365:1727–1741. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hatakeyama S: TRIM family proteins: Roles
in autophagy, immunity, and carcinogenesis. Trends Biochem Sci.
42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao G, Liu C, Wen X, Luan G, Xie L and
Guo X: The translational values of TRIM family in pan-cancers: From
functions and mechanisms to clinics. Pharmacol Ther.
227:1078812021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhan W and Zhang S: TRIM proteins in lung
cancer: Mechanisms, biomarkers and therapeutic targets. Life Sci.
268:1189852021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meroni G: TRIM E3 ubiquitin ligases in
rare genetic disorders. Adv Exp Med Biol. 1233:311–325. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Venuto S and Merla G: E3 ubiquitin ligase
TRIM proteins, cell cycle and mitosis. Cells. 8:5102019. View Article : Google Scholar :
|
|
10
|
Goyani S, Roy M and Singh R: TRIM-NHL as
RNA binding ubiquitin E3 ligase (RBUL): Implication in development
and disease pathogenesis. Biochim Biophys Acta Mol Basis Dis. Jan
6–2021.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Connacher RP and Goldstrohm AC: Molecular
and biological functions of TRIM-NHL RNA-binding proteins. Wiley
Interdiscip Rev RNA. 12. pp. e16202021, View Article : Google Scholar
|
|
12
|
Eberhardt W, Haeussler K, Nasrullah U and
Pfeilschifter J: Multifaceted roles of TRIM proteins in colorectal
carcinoma. Int J Mol Sci. 21:75322020. View Article : Google Scholar :
|
|
13
|
Watanabe M and Hatakeyama S: TRIM proteins
and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
|
|
14
|
Chen Z, Wang Z, Guo W, Zhang Z, Zhao F,
Zhao Y, Jia D, Ding J, Wang H, Yao M and He X: TRIM35 Interacts
with pyruvate kinase isoform M2 to suppress the warburg effect and
tumorigenicity in hepatocellular carcinoma. Oncogene. 34:3946–3956.
2015. View Article : Google Scholar
|
|
15
|
Wang R, Huang KL and Xing LX: TRIM35
functions as a novel tumor suppressor in breast cancer by inducing
cell apoptosis through ubiquitination of PDK1. Neoplasma.
69:370–382. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shulman RG and Rothman DL: The glycogen
shunt maintains glycolytic homeostasis and the warburg effect in
cancer. Trends Cancer. 3:761–767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lebelo MT, Joubert AM and Visagie MH:
Warburg effect and its role in tumourigenesis. Arch Pharm Res.
42:833–847. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kozal K, Jóźwiak P and Krześlak A:
Contemporary perspectives on the warburg effect inhibition in
cancer therapy. Cancer Control. Sep 23–2021.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johar D, Elmehrath AO, Khalil RM, Elberry
MH, Zaky S, Shalabi SA and Bernstein LH: Protein networks linking
warburg and reverse warburg effects to cancer cell metabolism.
Biofactors. 47:713–728. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zam W, Ahmed I and Yousef H: The warburg
effect on cancer cells survival: The role of sugar starvation in
cancer therapy. Curr Rev Clin Exp Pharmacol. 16:30–38. 2021.
View Article : Google Scholar
|
|
21
|
Yu H, Zhao K, Zeng H, Li Z, Chen K, Zhang
Z, Li E and Wu Z: N6-methyladenosine (m6A) methyltransferase WTAP
accelerates the warburg effect of gastric cancer through regulating
HK2 stability. Biomed Pharmacother. 133:1110752021. View Article : Google Scholar
|
|
22
|
Du Y, Wei N, Ma R, Jiang S and Song D: A
miR-210-3p regulon that controls the warburg effect by modulating
HIF-1α and p53 activity in triple-negative breast cancer. Cell
Death Dis. 11:7312020. View Article : Google Scholar
|
|
23
|
Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B
and Liu P: NCAPD3 enhances warburg effect through c-myc and E2F1
and promotes the occurrence and progression of colorectal cancer. J
Exp Clin Cancer Res. 41:1982022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Ganapathy-Kanniappan S and Geschwind JF:
Tumor glycolysis as a target for cancer therapy: Progress and
prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dayton TL, Jacks T and Vander Heiden MG:
PKM2, cancer metabolism, and the road ahead. EMBO Rep.
17:1721–1730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen
X and Peng C: Pyruvate kinase M2 (PKM2) in cancer and cancer
therapeutics. Cancer Lett. 503:240–248. 2021. View Article : Google Scholar
|
|
29
|
Zhang Z, Deng X, Liu Y, Liu Y, Sun L and
Chen F: PKM2, function and expression and regulation. Cell Biosci.
9:522019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zahra K, Dey T, Ashish, Mishra SP and
Pandey U: Pyruvate kinase M2 and cancer: The role of PKM2 in
promoting tumorigenesis. Front Oncol. 10:1592020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He X, Du S, Lei T, Li X, Liu Y, Wang H,
Tong R and Wang Y: PKM2 in carcinogenesis and oncotherapy.
Oncotarget. 8:110656–110670. 2017. View Article : Google Scholar
|
|
32
|
Ikeda K and Inoue S: TRIM proteins as RING
finger E3 ubiquitin ligases. Adv Exp Med Biol. 770:27–37. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Anastasiou D, Yu Y, Israelsen WJ, Jiang
JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, et al:
Pyruvate kinase M2 activators promote tetramer formation and
suppress tumorigenesis. Nat Chem Biol. 8:839–847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Popovic D, Vucic D and Dikic I:
Ubiquitination in disease pathogenesis and treatment. Nat Med.
20:1242–1253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cockram PE, Kist M and Prakash S:
Ubiquitination in the regulation of inflammatory cell death and
cancer. Cell Death Differ. 28:591–605. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zou T and Lin Z: The involvement of
ubiquitination machinery in cell cycle regulation and cancer
progression. Int J Mol Sci. 22:57542021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Senft D, Qi J and Ronai ZA: Ubiquitin
ligases in oncogenic transformation and cancer therapy. Nat Rev
Cancer. 18:69–88. 2018. View Article : Google Scholar :
|
|
38
|
Jia D, Wei L, Guo W, Zha R, Bao M, Chen Z,
Zhao Y, Ge C, Zhao F, Chen T, et al: Genome-wide copy number
analyses identified novel cancer genes in hepatocellular carcinoma.
Hepatology. 54:1227–1236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang J, Xu Z and Yu B, Xu J and Yu B:
Tripartite motif containing 35 contributes to the proliferation,
migration, and invasion of lung cancer cells in vitro and in vivo.
Biosci Rep. Apr 30–2020.Epub ahead of print.
|
|
40
|
Tan X, Cao F, Tang F, Lu C, Yu Q, Feng S,
Yang Z, Chen S, He X, He J, et al: Suppression of DLBCL Progression
by the E3 ligase Trim35 is mediated by CLOCK degradation and NK
cell infiltration. J Immunol Res. 24:99958692021.
|
|
41
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Z and Hunter T: Metabolic kinases
moonlighting as protein kinases. Trends Biochem Sci. 43:301–310.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iqbal MA, Gupta V, Gopinath P, Mazurek S
and Bamezai RN: Pyruvate kinase M2 and cancer: An updated
assessment. FEBS Lett. 588:2685–2692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li Z, Yang P and Li Z: The multifaceted
regulation and functions of PKM2 in tumor progression. Biochim
Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
|
|
45
|
Wong N, Ojo D, Yan J and Tang D: PKM2
contributes to cancer metabolism. Cancer Lett. 356:184–191. 2015.
View Article : Google Scholar
|
|
46
|
Zheng M, Xing W, Liu Y, Li M and Zhou H:
Tetramerization of SATB1 is essential for regulating of gene
expression. Mol Cell Biochem. 430:171–178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
French AC, Luscher B and Litchfield DW:
Development of a stabilized form of the regulatory CK2beta subunit
that inhibits cell proliferation. J Biol Chem. 282:29667–29677.
2007. View Article : Google Scholar : PubMed/NCBI
|
